| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
The specific molecular targets of Cixiophiopogon A have not been definitively established in publicly available literature. As a homoisoflavonoid, it is expected to interact with various cellular targets involved in inflammation, oxidative stress, and cell proliferation. Homoisoflavonoids are known to modulate signaling pathways such as NF-kappaB, MAPK, and PI3K/AKT, and to act as antioxidants by scavenging free radicals. Cixiophiopogon A may also interact with estrogen receptors due to the structural similarity of homoisoflavonoids to estrogens. Further studies are needed to identify its precise molecular targets and mechanisms of action.
|
|---|---|
| ln Vitro |
In vitro, Cixiophiopogon A is expected to exhibit biological activities characteristic of homoisoflavonoids, including anti-inflammatory, antioxidant, and anticancer properties. These activities would typically be assessed using cell-based assays, such as measuring the production of pro-inflammatory cytokines in LPS-stimulated macrophages, assessing free-radical scavenging capacity using DPPH or ABTS assays, or evaluating cytotoxicity against cancer cell lines using MTT or CCK-8 assays. However, specific data for Cixiophiopogon A are limited in the publicly available literature.
|
| ln Vivo |
In vivo, Cixiophiopogon A has potential applications in studying the pharmacological activities of homoisoflavonoids in animal models of inflammation, oxidative stress, and cancer. However, in vivo studies are limited, and further research is needed to evaluate its efficacy, pharmacokinetics, and safety in animal models. The compound's natural origin and structural similarity to other bioactive homoisoflavonoids suggest that it may have therapeutic potential, but additional studies are required to confirm this.
|
| Enzyme Assay |
Cell-free assays for Cixiophiopogon A would typically be designed based on its putative molecular targets or activities. For antioxidant activity, a common protocol for DPPH radical scavenging assay involves preparing a DPPH solution in methanol and incubating it with various concentrations of the compound at room temperature for 30 minutes. The absorbance is measured at 517 nm, and the percentage of radical scavenging activity is calculated. For anti-inflammatory activity, the compound's ability to inhibit NF-kappaB or MAPK signaling could be assessed using cell-free assays such as electrophoretic mobility shift assays (EMSA) or kinase activity assays.
|
| Cell Assay |
For in vitro cellular experiments, cells (e.g., macrophages, cancer cell lines) would be cultured in appropriate media and treated with Cixiophiopogon A at various concentrations (typically 1-100 uM). For anti-inflammatory studies, macrophages would be stimulated with LPS in the presence or absence of the compound, and the production of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6) would be measured by ELISA. For antioxidant studies, cells would be exposed to oxidative stress (e.g., H2O2) in the presence or absence of the compound, and oxidative stress markers (e.g., ROS, MDA) would be measured. Cell viability would be assessed using MTT or CCK-8 assays.
|
| Animal Protocol |
In vivo animal experiments with Cixiophiopogon A would typically involve oral or intraperitoneal administration in rodent models of inflammation, oxidative stress, or cancer. A common dosing regimen would be 10-50 mg/kg body weight, administered daily for 1-4 weeks. For anti-inflammatory studies, animals would be treated with the compound before or after induction of inflammation, and inflammatory markers would be measured in blood and tissue samples. For anticancer studies, tumor-bearing mice would be treated with the compound, and tumor growth would be monitored by caliper measurements. Blood and tissue samples would be collected for pharmacokinetic and biochemical analysis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Cixiophiopogon A are not well-documented in the available literature. As a homoisoflavonoid with a molecular weight in the range of 300-500 g/mol, it is expected to have moderate lipophilicity and may be orally bioavailable. However, its absorption, distribution, metabolism, and excretion properties have not been characterized. The compound is typically stored at -20degC and is stable in its pure form. Further pharmacokinetic studies are needed to determine its bioavailability, half-life, and tissue distribution.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Cixiophiopogon A has not been extensively characterized. As a natural product, it is expected to have a favorable safety profile at pharmacological doses. However, high doses may cause gastrointestinal discomfort or other mild adverse effects. The compound should be handled with standard laboratory precautions and is intended for research use only. Further toxicological studies are needed to establish its full safety profile.
|
| References | |
| Additional Infomation |
Reports indicate that Ophiopogon japonicus contains Cixiophiopogon A, and relevant data is available for reference.
Cixiophiopogon A (CAS 288143-27-1) is a naturally occurring homoisoflavonoid compound isolated from the roots of Ophiopogon japonicus, a plant used in traditional Chinese medicine. Homoisoflavonoids are known for their diverse biological activities, including anti-inflammatory, antioxidant, and anticancer properties. Cixiophiopogon A is a research compound with potential applications in studying the pharmacological activities of homoisoflavonoids. Detailed information about its specific biological activities and molecular targets is limited. The compound is available as a research compound and is not approved for clinical use. |
| Molecular Formula |
C44H70O18
|
|---|---|
| Molecular Weight |
887.0158
|
| Exact Mass |
886.456
|
| CAS # |
288143-27-1
|
| PubChem CID |
102004869
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.638
|
| LogP |
4.54
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
62
|
| Complexity |
1670
|
| Defined Atom Stereocenter Count |
25
|
| SMILES |
C[C@@H]1CC[C@@]2([C@H]([C@]3([C@@H](O2)C[C@@]4([C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)O)O)C)OC1
|
| InChi Key |
XEMVQWDHRXAQNR-YVEJFGEMSA-N
|
| InChi Code |
InChI=1S/C44H70O18/c1-19-8-13-43(56-17-19)21(3)44(54)28(62-43)15-42(53)25-7-6-22-14-23(9-11-40(22,4)24(25)10-12-41(42,44)5)58-39-36(61-38-34(52)32(50)29(47)20(2)57-38)35(31(49)27(16-45)59-39)60-37-33(51)30(48)26(46)18-55-37/h6,19-21,23-39,45-54H,7-18H2,1-5H3/t19-,20+,21-,23+,24+,25-,26-,27-,28+,29+,30+,31-,32-,33-,34-,35+,36-,37+,38+,39-,40+,41+,42-,43-,44-/m1/s1
|
| Chemical Name |
(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5R,6R)-2-[(1R,2R,4S,5'R,6R,7S,8S,9S,12S,13R,16S)-2,8-dihydroxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxy-5-hydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~56.37 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (1.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (1.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (1.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1274 mL | 5.6369 mL | 11.2737 mL | |
| 5 mM | 0.2255 mL | 1.1274 mL | 2.2547 mL | |
| 10 mM | 0.1127 mL | 0.5637 mL | 1.1274 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
